Believe it or not: how much can we rely on published data on potential drug targets?
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“reports from the pharmaceutical industry (Begley & Ellis, 2012;Prinz et al., 2011) and systematic assessments of replicability in specific fields, such as cancer biology (Errington, Mathur, et al., 2021), spinal cord injury (Steward et al., 2012) and amyotrophic lateral sclerosis (Scott et al., 2008), have reported success rates ranging from 0 to 40%.”
From Estimating the replicability of Brazilian biomedical science (2025) · cites this paper as Prinz et al., 2011
In the citing paper
“These numbers are in a similar range as previous estimates from the biomedical literature (Begley & Ellis, 2012;Errington, Mathur, et al., 2021;Prinz et al., 2011;Scott et al., 2008;Steward et al., 2012).”
From Estimating the replicability of Brazilian biomedical science (2025) · cites this paper as Prinz et al., 2011
In the citing paper
“This may contribute to publication bias, selective reporting, and questionable research practices that reduce the credibility of the published literature 18-25 .”
From Initial evidence of research quality of registered reports compared with the standard publishing model (2021) · cites this paper as [19]
In the citing paper
“Scientists at Bayer have reported that only ~25% of published preclinical studies could be validated to the point at which projects could progress.2”
From Reproducibility of Quantitative Systems Pharmacology Models: Current Challenges and Future Opportunities (2019) · cites this paper as [2]
In the citing paper
“A team at Bayer HealthCare in Germany last year reported 4 that only about 25% of published preclinical studies could be validated to the point at which projects could continue.”
From Raise standards for preclinical cancer research (2012) · cites this paper as [4]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2019) · CHANCE · doi:10.1080/09332480.2019.1579573 · Cited by 463
What errors do peer reviewers detect, and does training improve their ability to detect them?
Schroter, S., Black, N., Evans, S., Godlee, F., Osorio, L., & Smith, R. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.080062 · Cited by 226
Osherovich, L. Z. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.416 · Cited by 43
Factors Affecting Reproducibility between Genome-Scale siRNA-Based Screens
Barrows, N. J., Sommer, C. L., Garcia-Blanco, M. A., & Pearson, J. L. (2010) · SLAS Discovery · doi:10.1177/1087057110374994 · Cited by 39
McDonald, R. J., Cloft, H. J., & Kallmes, D. F. (2007) · American Journal of Neuroradiology · doi:10.3174/ajnr.a0766 · Cited by 31
Nemery, B. (2001) · Occupational and Environmental Medicine · doi:10.1136/oem.58.9.604 · Cited by 23 · cited 1×
“Adding to this problem, many initially rejected papers will subsequently be published in other journals without substantial changes or improvement”
Background
Research works printed but not linked: 2
- Lehrer, J. The truth wears off: is there something wrong with the scientific method? The New Yorker [online], (2010).
- Freeman, D. H. Lies, damned lies, and medical science. The Atlantic [online], (2010).
Cited by
Items 801–900 of 1,001
Understanding of researcher behavior is required to improve data reliability
Wass, M. N., Ray, L., & Michaelis, M. (2019) · GigaScience · doi:10.1093/gigascience/giz017 · Cited by 22
Personalized Pain Medicine: Pipe Dream or Reality?
Bruehl, S. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000638 · Cited by 14
The Best Model of a Cat Is Several Cats
Gustafsson, C., & Vallverdú, J. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.12.006 · Cited by 18
“In a series of recent publications, the reproducibility of landmark oncology studies are questioned [36], drug target models are often inaccurate [37], and non-confirmatory findings are difficult to publish [38].”
BackgroundMulhall, P., Taggart, L., McAloon, T., & COATES, V. E. (2020) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/jar.12838 · Cited by 15
Ahmad, R., Riaz, M., Aldholmi, M., Qureshi, M. A., Uddin, S., Bhat, A., Pratheeshkumar, P., Baig, M., Pourahmad, J., Ganesan, T., et al. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.12.3735 · Cited by 16
“In addition, the pharmaceutical firms also expressed their concern with the claimed 25% reproducibility of pre-clinical trials (Prinz et al., 2011).”
BackgroundCheckMyMetal ( CMM ): validating metal-binding sites in X-ray and cryo-EM data
Gucwa, M., Bijak, V., Zheng, H., Murzyn, K., & Minor, W. (2024) · IUCrJ · doi:10.1107/s2052252524007073 · Cited by 18
Translating Neurogenomics Into New Medicines
Wendland, J. R., & Ehlers, M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.027 · Cited by 17
Becker, R. E., Seeman, M. V., Greig, N. H., & Lahiri, D. K. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00214-x · Cited by 16
The Problem of Biased Data and Potential Solutions for Health and Environmental Assessments
Suter, G. W., & Cormier, S. M. (2014) · Human and Ecological Risk Assessment An International Journal · doi:10.1080/10807039.2014.974499 · Cited by 17
“Bayer scientists could replicate only 35% of 67 published drug tests (Mullard 2011; Prinz et al. 2011).”
BackgroundThe distribution of probability values in medical abstracts: an observational study
Ginsel, B. L., Aggarwal, A., Xuan, W., & Harris, I. A. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1691-x · Cited by 15
“literature [21–23].”
Huang, M. C., Ma, Q., Liu, X., Li, B., & Ma, H. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00694 · Cited by 15
Siebenga, P. S., van Amerongen, G., Okkerse, P., Denney, W. S., Dua, P., Butt, R. P., Hay, J. L., & Groeneveld, G. J. (2019) · European Journal of Pain · doi:10.1002/ejp.1379 · Cited by 17
“Unfortunately, however, the reproducibility of major findings published in high‐profile journals is strikingly low, ranging from 10% to 25% (Peers, Ceuppens, & Harbron, 2012; Prinz et al., 2011).”
BackgroundHelliwell, J. R., Minor, W., Weiss, M. S., Garman, E. F., Read, R. J., Newman, J. M., van Raaij, M. J., Hajdu, J., & Baker, E. N. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319004844 · Cited by 15
Tsvetkov, D., Kolpakov, E., Kaßmann, M., Schubert, R., & Gollasch, M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00126 · Cited by 17
“Some data have indicated that only 20 % of studies published even in prestige journals can be replicated (14).”
BackgroundSchätzle, L.-K., Esfahani, A. H., & Schuppert, A. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007803 · Cited by 20
Smith, A. J., Lambert, P. C., & Rutherford, M. J. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01654-1 · Cited by 15
KHAN, I. A., Bai, Y., Ullah, N., Liu, G., Rajoka, M. S. R., & Zhang, C. (2022) · Advanced Gut & Microbiome Research · doi:10.1155/2022/7813278 · Cited by 24
“Owing to reproducibility issues, several preclinical research studies using animal models have been controversial and have not been validated [45, 46].”
BackgroundBasic Statistics in Cell Biology
Vaux, D. L. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013303 · Cited by 15
Challenges in Applying the Results of Clinical Trials to Clinical Practice
Zarbin, M. A. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.1266 · Cited by 16
Cherry‐Allen, K. M., Gidday, J. M., Lee, J., Hershey, T. G., & Lang, C. E. (2016) · Journal of Motor Behavior · doi:10.1080/00222895.2016.1204268 · Cited by 17
Cognitive Bias in Medicolegal Death Investigation
Oliver, W. R., Fudenberg, J., Howe, J. A., & Thomas, L. C. (2015) · Academic Forensic Pathology · doi:10.23907/2015.060 · Cited by 16
The Academic–Industrial Complexity: Failure to Launch
Levin, L. A., & Béhar‐Cohen, F. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.003 · Cited by 15
“Bayer found that only 20–25% of academic findings could be reproduced by their in-house team [3], and Amgen found only 11% [4].”
BackgroundThe Elements of Translational Chemical Biology
Copeland, R. A., & Boriack‐Sjodin, P. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.11.003 · Cited by 15
Of mice and men: long-term safety of assisted reproduction treatments
Sharpe, R. M. (2018) · Human Reproduction · doi:10.1093/humrep/dey071 · Cited by 17
Inconsistency of findings due to low power: A structural MRI study of bilingualism
Munson, B. A., & Hernández, A. E. (2019) · Brain and Language · doi:10.1016/j.bandl.2019.104642 · Cited by 15
Sivakova, O. V., Pokrovskaya, M. S., Metelskaya, V. A., Limonova, A. S., Meshkov, A. N., & Drapkina, O. M. (2019) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20192206295 · Cited by 15
Data to knowledge: how to get meaning from your result
Berman, H. M., Gabanyi, M. J., Groom, C. R., Johnson, J. E., Murshudov, G. N., Nicholls, R. A., Reddy, V. S., Schwede, T. F., Zimmerman, M. D., Westbrook, J., et al. (2014) · IUCrJ · doi:10.1107/s2052252514023306 · Cited by 15
“Several elite speakers were invited to present their work and future plans in a wide range of fields that can improve this conversion and have an impact on the issue of reproducibility of results (Carp, 2013; Collins & Tabak, 2014; Franzoni et al., 2011; Prinz et al., 2011).”
BackgroundJanero, D. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.685154 · Cited by 15
“This difference may contribute to difficulties that pharma-industry laboratories have expressed in reproducing published data and the debate regarding the extent to which a non-commercial entity can generate useful drugs [8,9].”
BackgroundReporting In Vitro Experiments Responsibly – the RIVER RecommendationsPreprint
The RIVER working group (2023) · MetArXiv (OSF Preprints) · doi:10.31222/osf.io/x6aut · Cited by 25
Future Viable Models of Psychiatry Drug Discovery in Pharma
Rizzo, S. J. S., Edgerton, J. R., Hughes, Z. A., & Brandon, N. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113475871 · Cited by 14
“With research groups purportedly failing to reproduce a large proportion of published findings (some estimates as high as 50%), it clearly sets up for significant attrition in later development.(50) We are certainly not the first to suggest that publishing negative data should be a welcomed opportunity, but we also en…”
BackgroundResultThe Life Sciences Translational Challenge: The European Perspective
Barker, R., & Scannell, J. W. (2015) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014561340 · Cited by 18
“Estimates of the proportion of irreproducible science vary, but on some measures, more than 70% of results published in high-quality biomedical journals cannot be replicated in industrial laboratories.(36,37) There are also some striking disease-specific examples.”
BackgroundTempest in a teacup: An analysis of p-Hacking in organizational research
Gupta, A., & Bosco, F. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281938 · Cited by 19
Popov, P. A., Kalinin, R. E., Buslaev, P., Kozlovskii, I., Zaretckii, M., Karlov, D. S., Gabibov, A. G., & Stepanov, A. V. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad459 · Cited by 14
“Unfortunately, target and binding site identification is not straightforward and can arguably be considered one of the most challenging and critical parts of the drug discovery campaign [3,4].”
BackgroundDaugherty, A., Hegele, R. A., Mackman, N., Rader, D. J., Schmidt, A. M., & Weber, C. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307906 · Cited by 15
In vitro models of the human microbiota and microbiome
McDonald, J. A. K. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170045 · Cited by 25
A Theory of Statistical Inference for Ensuring the Robustness of Scientific Results
Coker, B., Rudin, C. D., & King, G. (2021) · Management Science · doi:10.1287/mnsc.2020.3818 · Cited by 42
The Potential Effect of the 21st Century Cures Act on Drug Development
Goble, J. A. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.7.677 · Cited by 14
“of potential drug targets or biomarkers have inconsistencies when attempting to reproduce findings.(13) Also, some surrogate”
BackgroundBio-Curation for Cellular Signalling: The KAMI Project
Harmer, R., Cornec, Y.-S. L., Légaré, S., & Oshurko, E. (2019) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2019.2906164 · Cited by 14
“…a de-contextualized representation of PPIs—to address the critical issue of reproducibility and robustness of biological knowledge [18], [19]: if a single body of de-contextualized knowledge can be instantiated to a number of different cell type contexts, providing pertinent…”
Powell, D. R., Revelli, J., Doree, D. D., DaCosta, C. M., Desai, U., Shadoan, M. K., Rodriguez, L., Mullens, M., Yang, Q. M., Ding, Z., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s322083 · Cited by 16
Vasconcelos, A. L., Campbell, M. J., Barratt, C. L. R., & Gellatly, S. A. (2022) · Human Reproduction · doi:10.1093/humrep/deac173 · Cited by 17
“During the last decade, several authors have published concerns about the reproducibility, transparency and reliability of published results in scientific research (Ioannidis, 2005; Prinz et al., 2011).”
BackgroundBox, W. J., Webb, M. T., & Galizia, M. (2022) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.2c01414 · Cited by 14
Lubega, N., Anderson, A., & Nelson, N. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293584 · Cited by 16
“Reports from pharmaceutical companies of replication rates as low as 11–39% in preclinical research [1,2] have catalyzed discussion about reproducibility and rigor in the past decade [3].”
BackgroundDrug discovery in focal and segmental glomerulosclerosis
Pullen, N., & Fornoni, A. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.058 · Cited by 14
Grogan, T., & Elashoff, D. A. (2017) · Communications in Statistics - Simulation and Computation · doi:10.1080/03610918.2016.1230216 · Cited by 18
“Similar findings were reported by a group at Bayer HealthCare in Germany where only 25% of the published papers which they were basing their research and development projects on could be categorized as reproducible (Prinz et al., 2011).”
ResultSingh, S., Srivastava, A., Srivastava, P., Dhuriya, Y. K., Pandey, A., Kumar, D., & Rajpurohit, C. S. (2016) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2016.00072 · Cited by 16
A very simple, re-executable neuroimaging publication
Ghosh, S., Poline, J., Keator, D. B., Halchenko, Y. O., Thomas, A. G., Kessler, D. A., & Kennedy, D. N. (2017) · F1000Research · doi:10.12688/f1000research.10783.2 · Cited by 13
“A number of studies have brought the reproducibility of science into question (Prinz et al. , 2011).”
Fu, J., Fernandez, D. J., Ferrer, M., Titus, S. A., Buehler, E. C., & Lal‐Nag, M. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217696796 · Cited by 13
“Although HTS tools and methods enable the collection of data on the genomewide scale, screens are limited by the same technical aspects of current in vitro assay systems in low throughput that have proven to be unable to provide robust, high-priority targets that can withstand extensive validation.(4) Cell-based proli…”
MethodQuality assurance and best research practices for non-regulated veterinary clinical studies
Davies, R., London, C. A., Lascelles, B. D. X., & Conzemius, M. G. (2017) · BMC Veterinary Research · doi:10.1186/s12917-017-1153-x · Cited by 17
Ng, K. P., Manjeri, A., Lee, L. M., Chan, Z. E., Tan, C. Y., Tan, Q. D., Majeed, A., Lee, K. L., Chuah, C. T. H., Suda, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205254 · Cited by 14
Rhetorical Citizenship and the Science of Science Communication
Fahnestock, J. (2019) · Argumentation · doi:10.1007/s10503-019-09499-7 · Cited by 17
Transparency and openness in behavioral medicine research
McVay, M. A., & Conroy, D. E. (2019) · Translational Behavioral Medicine · doi:10.1093/tbm/ibz154 · Cited by 11
Physics approaches to the spatial distribution of immune cells in tumors
Yu, C. C., Wortman, J. C., He, T.-F., Solomon, S. T., Zhang, B., Rosario, A., Wang, R., Tu, T. Y., Schmolze, D. D., Yuan, Y., et al. (2021) · Reports on Progress in Physics · doi:10.1088/1361-6633/abcd7b · Cited by 18
Jansen, C., Annuscheit, J., Schilling, B., Strohmenger, K., Witt, M., Bartusch, F., Herta, C., Hufnagl, P., & Krefting, D. (2020) · Future Generation Computer Systems · doi:10.1016/j.future.2020.05.007 · Cited by 16
Michel, M. C., Murphy, T. J., & Motulsky, H. J. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.090027 · Cited by 14
(2013) · Nature Chemical Biology · doi:10.1038/nchembio.1269 · Cited by 14
Estimating the replicability of Brazilian biomedical science
Initiative, T. B. R., Amaral, O. B., Carneiro, C. F. D., Neves, K., Sampaio, A. P. W., Gomes, B. V., Abreu, M. B. D., Tan, P. B., Mota, G. P. S., Goulart, R. N., et al. (2025) · bioRxiv · doi:10.1101/2025.04.02.645026 · Cited by 13
“Basic biomedical science has not been immune to these concerns: reports from the pharmaceutical industry (Begley & Ellis, 2012; Prinz et al., 2011) and prospective assessments of replicability in specific fields, such as cancer biology (Errington, Mathur, et al., 2021), spinal cord injury (Steward…”
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science
Groothuis, P. G., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719118785767 · Cited by 13
The mouse multi-organ proteome from infancy to adulthood
Wang, Q., Ding, X., Xu, Z., Wang, B., Wang, A., Wang, L., Ding, Y., Song, S., Chen, Y., Zhang, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50183-6 · Cited by 17
“To further investigate the function of age-unique proteins, we used DAVID to conduct an enrichment analysis of age-unique proteins in corresponding time points (Supplement Data 16).”
Schatz, G. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3807 · Cited by 13
Janero, D. R. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.925876 · Cited by 14
“The fact that insufficient efficacy was the most frequent cause of Phase II clinical failures occurring during 2008 -- 2011 and regulatory rejection of new molecular entities by the United States FDA during 2000 -- 2012 [82,83] strongly suggests that limitations of established disease models within canonical, target-b…”
BackgroundThe path to VICTORy – a beginner's guide to success using commercial research antibodies
Goodman, S. L. (2018) · Journal of Cell Science · doi:10.1242/jcs.216416 · Cited by 14
“In the past decade, efforts to reproduce many pivotal studies in oncology, on which drug developments were based, failed (Begley and Ellis, 2012; Freedman et al., 2015; Prinz et al., 2011), and these were data published in respected, well cited journals.”
BackgroundTHE FAIR REWARD PROBLEM: THE ILLUSION OF SUCCESS AND HOW TO SOLVE IT
Sornette, D., Wheatley, S., & Cauwels, P. P. (2019) · Advances in Complex Systems · doi:10.1142/s021952591950005x · Cited by 14
“Bayer HealthCare arrived at a 25% reproduction/validation (Prinz et al., 2011).”
Neuroethics: Fostering Collaborations to Enable Neuroscientific Discovery
Farahany, N. A., & Ramos, K. M. (2020) · AJOB Neuroscience · doi:10.1080/21507740.2020.1778117 · Cited by 17
“and others) toward improved models for studying the human brain and its diseases is critical, since it is well-appreciated that many model systems—including animal ones—have limitations in their approximation of the human brain (Begley and Ellis 2012; Prinz et al. 2011).”
BackgroundTranslating Laboratory Tests into Clinical Practice: A Conceptual Framework
Nagler, M. (2020) · Hämostaseologie · doi:10.1055/a-1227-8008 · Cited by 15
Brown, H. M., Kuhns, M. M., Maxwell, Z. A., & Arriaga, E. A. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03211 · Cited by 14
de Jong, J. M., Hoogendam, J. P., Braat, A. J. A. T., Zweemer, R. P., & Gerestein, C. G. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.05.017 · Cited by 14
Wu, Y., Wu, X., Gao, L., Yan, Y., Geng, Z., Zhou, S., Zhu, W., Tian, Y., Yu, Y., Wei, L., et al. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.06.006 · Cited by 16
Scholz, C., Chan, H., Poldrack, R. A., de Ridder, D. T. D., Smidts, A., & van der Laan, L. N. (2022) · Human Brain Mapping · doi:10.1002/hbm.26065 · Cited by 15
“Although growing concern about the reproducibility of scientific findings (the “replication crisis”) has led to several replication projects in fields like social psychology (Open Science Collaboration, 2015) and biomedical research (Prinz et al., 2011), replication remains uncommon in neuroscience.”
BackgroundOpen for collaboration: an academic platform for drug discovery and development at SciLifeLab
Arvidsson, P. I., Sandberg, K., & Forsberg‐Nilsson, K. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.026 · Cited by 12
Theory and practice of clinical pharmacodynamics in oncology drug development
Parchment, R. E., & Doroshow, J. H. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.07.001 · Cited by 13
Study Design Rigor in Animal-Experimental Research Published in Anesthesia Journals
Hoerauf, J. M., Moss, A. F. D., Fernandez-Bustamante, A., & Bartels, K. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001907 · Cited by 12
The role of the IACUC in ensuring research reproducibility
Silverman, J., Macy, J. D., & Preisig, P. A. (2017) · Lab Animal · doi:10.1038/laban.1213 · Cited by 17
Godecharle, S., Nemery, B., & Dierickx, K. (2017) · Science and Engineering Ethics · doi:10.1007/s11948-017-9965-4 · Cited by 14
Collaboration and competition: ethics in toxicology
Walker, E. S., & Roberts, R. A. (2018) · Toxicology Research · doi:10.1039/c7tx00306d · Cited by 13
Grant, M. K. O., Shapiro, S. L., Ashe, K. H., Liu, P., & Zahs, K. R. (2019) · Biological Procedures Online · doi:10.1186/s12575-019-0095-z · Cited by 14
In vivoobservations provide insight into roles of eosinophils and epithelial cells in asthma
Persson, C. G. A. (2019) · European Respiratory Journal · doi:10.1183/13993003.00470-2019 · Cited by 13
Prediction and Experimental Confirmation of Novel Peripheral Cannabinoid‑1 Receptor Antagonists
El-Atawneh, S., Hirsch, S., Hadar, R., Tam, J., & Goldblum, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00577 · Cited by 14
Comparative Medicine: An Inclusive Crossover Discipline.
Macy, J. D., & Horváth, T. L. (2017) · PubMed Central · Cited by 17
Sipido, K. R., & Nagyová, I. (2020) · European Journal of Public Health · doi:10.1093/eurpub/ckaa032 · Cited by 17
Evidenzbasierte | evidenzinformierte Gesundheitskommunikation
Erfurt, D. G. F. P. U. K. 2., Stehr, P., Heinemeier, D., Rossmann, C., & Verlagsgesellschaft, N. (2018) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783845291963 · Cited by 12
Lebendiker, M., Danieli, T., & de Marco, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-585 · Cited by 12
Public–Private Partnerships in Lead Discovery: Overview and Case Studies
Gottwald, M., Becker, A., Bahr, I., & Mueller‐Fahrnow, A. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201600078 · Cited by 13
Gunn, W. (2014) · Nature · doi:10.1038/505483b · Cited by 12
Reporting of Results from Animal Studies
Tilson, H. A., & Schroeder, J. C. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1307676 · Cited by 13
“In addition, Prinz et al. (2011) reported that almost twothirds of 67 inhouse preclinical cancer projects did not replicate data previously published by others.”
BackgroundQuality really matters: the need to improve specimen quality in biomedical research
Simeon‐Dubach, D., Burt, A. D., & Hall, P. A. (2012) · Histopathology · doi:10.1111/his.12060 · Cited by 13
“Therefore findings of low reproducibility of published scientific data as reported recently by two different groups are perhaps not surprising.(6,7) It will take some time and significant effort to sort this sorry situation out.”
BackgroundSardanelli, F., & Colarieti, A. (2022) · La radiologia medica · doi:10.1007/s11547-022-01582-6 · Cited by 13
“[4] were successful in 20 − 25% of cases.”
BackgroundEverts, M., & Drew, M. D. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2284824 · Cited by 12
“Even beyond this issue, reproducibility of research findings is a major problem, with an estimate of only 20–25% being reproduced by an independent group [14].”
BackgroundInfluentialGreenfeld, M., van de Meent, J.-W., Pavlichin, D. S., Mabuchi, H., Wiggins, C. H., Gonzalez, R. L., & Herschlag, D. (2015) · BMC Bioinformatics · doi:10.1186/s12859-014-0429-4 · Cited by 15
“try where the reproducibility of scientific results has been questioned [17-20] has raised awareness that a lack of easy access to raw data (arising from many”
BackgroundSchachter, B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2385 · Cited by 12
George, B. J., Sobus, J. R., Phelps, L. P., Rashleigh, B., Simmons, J. E., Hines, R. N., & Groups, T. C. O. P. F. S. G. D. W. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv020 · Cited by 15
“…were the lack of appropriate statistical considerations, including inadequate attention to power, failure to consider bias during study design, less than rigorous or simply flawed data analysis, and failure to include adequate methods descriptions (Begley and Ellis, 2012; Prinz et al., 2011).”
InfluentialHatley, R. J. D., Macdonald, S. J. F., Slack, R. J., Le, J., Ludbrook, S. B., & Lukey, P. T. (2017) · Angewandte Chemie · doi:10.1002/ange.201707948 · Cited by 13
Building a Professional Identity and an Academic Career Track in Translational Medicine
van Dijk, S. J., Domenighetti, A. A., Gomez‐Ospina, N., Hunter, P., Lindemans, C. A., Melotte, V., van Rossum, A. M. C., & Rosenblum, N. D. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00151 · Cited by 12
Statistical Rigor and the Perils of Chance
Button, K. S. (2016) · eNeuro · doi:10.1523/eneuro.0030-16.2016 · Cited by 12
“…could not be replicated (Scott et al., 2008; Begley and Ellis, 2012; Steward et al., 2012) and many promising preclinical findings have failed to translate into clinical application (Perel et al., 2007; Prinz et al., 2011), leading many to question whether science is broken (Economist,2013).”
BackgroundTraining to Improve Precision and Accuracy in the Measurement of Fiber Morphology
Hotaling, N. A., Jeon, J., Wade, M. B., Luong, D., Palmer, X., Bharti, K., & Simon, C. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167664 · Cited by 11
Mikó, Z., Ujszegi, J., Gál, Z., & Hettyey, A. (2017) · Archives of Environmental Contamination and Toxicology · doi:10.1007/s00244-017-0427-4 · Cited by 14
“Replicability problems of scientific results have surfaced recently within various fields, such as cancer biology, drug discovery, or psychology (Prinz et al. 2011; Begley and Ellis 2012; Open Science Collaboration 2015).”
BackgroundChung, S., & Fink, E. L. (2018) · Annals of the International Communication Association · doi:10.1080/23808985.2018.1425100 · Cited by 13
Vollert, J., Schenker, E., Macleod, M. R., Bespalov, A., Würbel, H., Michel, M. C., Dirnagl, U., Potschka, H., Wever, K. E., Steckler, T., et al. (2018) · BMJ Open Science · doi:10.1136/bmjos-2018-000004 · Cited by 14
Osimani, B. (2020) · Boston studies in the philosophy of science · doi:10.1007/978-3-030-29179-2_15 · Cited by 13
Beyond Standardization: Improving External Validity and Reproducibility in Experimental Evolution
Desjardins, E., Kurtz, J., Kranke, N., Lindeza, A. S., & Richter, S. H. (2021) · BioScience · doi:10.1093/biosci/biab008 · Cited by 12
Quality management for robust and reliable research
Giesen, E. (2015) · International Journal of Metrology and Quality Engineering · doi:10.1051/ijmqe/2015029 · Cited by 16
Metadata
- Authors
- Prinz, F., Schlange, T., & Asadullah, K.
- Affiliations
- Bayer (Germany) (DE)
- Corresponding author
- Asadullah, Khusru
- ORCID
- Schlange, Thomas
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-08-31
- Volume
- 10
- Issue
- 9
- Pages
- 712-712
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2067833766
- Cited by
- 1,888
- References
- 8
- Citations by year
- 2026: 56 · 2025: 60 · 2024: 86 · 2023: 108 · 2022: 138 · 2021: 126 · 2020: 131 · 2019: 171 · 2018: 147 · 2017: 176 · 2016: 202 · 2015: 183 · 2014: 141 · 2013: 98 · 2012: 57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- therapeutic target, reproducibility, publication bias, false positives, peer review, manuscript rejection, siRNA screen, drug target validation
- MeSH terms
- Drug Industry, Humans, Drug Design, Clinical Trials, Phase II as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.